BIRMINGHAM, Ala.--(BUSINESS WIRE)--ProAssurance Corporation (NYSE: PRA), an industry-leading specialty insurer with extensive expertise in medical professional liability, today reported net income of $21.9 million, or $0.42 per diluted share, and operating income(1) of $26.8 million, or $0.52 per diluted share, for the three months ended June 30, 2025. For the six months ended June 30, 2025, net income was $16.1 million, or $0.31 per diluted share, and operating income was $33.6 million, or $0.
Related Questions
How does ProAssurance’s Q2 performance stack up against key competitors in the medical professional liability space (e.g., CNA, HRT, Tokio)?
How might the results influence the stock’s valuation multiples (P/E, P/B) relative to historical levels?
What is the impact of recent medical malpractice claim developments on future profitability and loss reserves?
What macro‑economic or regulatory factors could materially affect ProAssurance’s earnings trajectory in the coming months?
Are there any notable changes in reinsurance arrangements or expense ratios that could affect next‑quarter results?
Did management provide any guidance or outlook for the balance‑sheet, underwriting cycle, or claim trends going forward?
Did the release mention any capital allocations, dividend policy, or share repurchase activity that could affect cash flow and shareholder returns?
How does the reported EPS of $0.42 per diluted share compare to Wall Street consensus estimates?
What was the operating margin for the quarter and the six‑month period, and how does it compare to prior periods?
What was the year‑over‑year change in net income and operating income for Q2 2025 compared to Q2 2024?